Pfizer Medications - Search News

Pfizer to Acquire Obesity Drug Start-Up Metsera

Pfizer Wins Obesity Drug Battle, With Assist by Trump’s FTC

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.

· 1d · on MSN

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

· 3d

Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

· 19h

Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B

The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity drug developer Metsera MTSR is finally over.

· 1d

Pfizer wins bidding war for obesity drug startup

· 1d

Novo Nordisk shares rise after dropping Metsera bid

Becker's Hospital Review

The Trump administration’s drug pricing deals, explained

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

17m

Where Will Pfizer Be in 3 Years?

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

2hon MSN

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

STAT

The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.

6hon MSN

Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo Nordisk ( NVO +0.47%) and Eli Lilly ( LLY +4.57%) slugging it out, while Pfizer ( PFE 0.16%) is looking to enter the fray.